Medical Isotope Production by Electron Accelerators. R.S. Orr University of Toronto

Similar documents
Producing Molybdenum-99 in CANDU Reactors. Jerry M Cuttler Cuttler & Associates Inc. Abstract

The Future of LEU in the Global Mo-99 Supply Chain

HEU MINIMISATION CHALLENGES. THE SUPPLY OF THE MEDICAL ISOTOPE 99-MOLYBDENUM/99m- TECHNETIUM

The Current State of Mo-99 Supply and the Conversion to LEU

The 99 Mo Supply Chain for Nuclear Medicine

A Supply and Demand Update of the Molybdenum-99 Market

The medical isotope crisis

CORAR Council on Radionuclides and Radiopharmaceuticals, Inc.

ENSURING RELIABLE MEDICAL ISOTOPE SUPPLY

The Economics of Reactor Produced Mo-99

Australia s unique leadership role

Staged Introduction of Non-power and Power Nuclear Technologies to Newcomer Countries. Mitsuru Uesaka

Meeting the moly-99 challenge

Global Threat Reduction Initiative

Supplying Molybdenum-99 to Global Markets. Kennedy Mang era Chief Operating Officer

REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Operation of the High Flux Reactor in the years {SWD(2018) 46 final}

International Perspective on non-heu Mo-99 Production

High-Level Group on the Security of Supply of Medical Radioisotopes

ANSTO Nuclear Medicine: Reliable and Timely Mo-99 Supply Globally

Global Threat Reduction Initiative

The "Réacteur Jules Horowitz" : The preliminary design

medicine represents more than 20 Billion $ in medical fees 99m Tc are conducted in the world. This not only is

Regulatory Experience and Developments Related to Accelerator Isotope Production

Global Threat Reduction Initiative

On the Practical Use of Lightbridge Thorium-based Fuels for Nuclear Power Generation

Reactor Schedule Coordination for Molybdenum-99 Supply Reliability

Charles Grant. International Centre for Environmental and Nuclear Sciences University of the West Indies

REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Operation of the High Flux Reactor in the period

Supply of Medical Radioisotopes. IPET Vienna October 10, Kevin Charlton Nuclear Development Division OECD/NEA

Regulatory Challenges and Solutions High-Enriched to Low-Enriched Uranium Fuel Conversion

World status on reactor and cyclotron radioisotope production

Nuclear Energy Fundamentals

Status of Mo-99 Supply and New Developments

Legislative Framework for the Regulation of Decommissioning at Egypt. Prof. Dr. Farouk M. A. Rahman

Acceptance and Disposition of Department of Energy Spent Nuclear Fuel

DOSE CALCULATION FOR ACCIDENT SITUATIONS AT TRIGA RESEARCH REACTOR USING LEU FUEL TYPE

Nuclear Reactors. 3 Unit Nuclear Power Station - Coastal Bryon Nuclear Plant, Illinois. 3 Unit Nuclear Power Station - Desert

Safety and Security of Supply of Medical Isotope Production

A Network Model and Computational Approach for the 99 Mo Supply Chain for Nuclear Medicine

a Cyclotron based European Multipurpose ADS for R&D (MYRRHA)

SAFETY ANALYSIS AND ASSESSMENT FOR TEMPORARY STORAGE OF 106 IRRADIATED VVR-M2 FUEL TYPE ASSEMBLIES IN DALAT REACTOR

ARIEL II: Completion to Science

Accelerate the Accelerators?! David Nusbaum

1. NUCLEAR REACTORS FOR THE PRODUCTION OF MOLYBDENUM-99

Nuclear Research Reactor TRIGA IAN-R1. Jaime Sandoval Lagos Supervisor Reactor Nuclear October 2014

THE ACCELERATOR PRODUCTION OF TRITIUM PROJECT

Molten Salt Reactor Technology for Thorium- Fueled Small Reactors

JORDAN RESEARCH AND TRAINING REACTOR UTILIZATION FACILITIES

OPAL. Australia s Research Reactor. Greg Storr

Department of Energy Spent Nuclear Fuel - Update. Outline

Present Status of Kyoto University Research Reactor, KUR

Perma-Fix Medical. Investor Presentation January 2016

COMPARATIVE STUDY OF TRANSIENT ANALYSIS OF PAKISTAN RESEARCH REACTOR-1 (PARR-1) WITH HIGH DENSITY FUEL

Lecture (3) on. Nuclear Reactors. By Dr. Emad M. Saad. Mechanical Engineering Dept. Faculty of Engineering. Fayoum University

6/6 Zoom out from centre. 8/14 Pan right zoom in bottom right 10/24 Zoom in center

Working Group 4 (WG4) Capacity and Infrastructure Development. July, 2014

Structural Concerns with the Global Nuclear Fuel Industry May 31,

Examples of Research Reactor Conversion Assessment of Alternatives

Safety Analysis of the MIT Nuclear Reactor for Conversion to LEU Fuel

Unique Irradiation Rigs developed for the HFR Petten at the JRC-IE;

Science of Nuclear Energy and Radiation

The Threat Posed by HEU, and Legislation to Reduce Bomb- Grade Uranium Commerce

THE ROLE OF A RESEARCH REACTOR IN THE NATIONAL NUCLEAR ENERGY PROGRAMME IN VIETNAM: PRESENT AND FUTURE

Safeguards at research reactors: Current practices, future directions

Multivariate Optimization of High Brightness High Current DC Photoinjector. Ivan Bazarov, Cornell University

Sustaining Material Testing Capacity in France: From OSIRIS to JHR

Multipurpose Research Reactor (RMB) Project Status. José Augusto Perrotta CNEN - Brazil

NIIEFA Accelerators for Industry and Medicine

IAEA assistance in RI production and supply: 99 Mo case

KIPT ACCELERATOR DRIVEN SYSTEM DESIGN AND PERFORMANCE

IAEA SUPPORT ACTIVITIES FOR RESEARCH REACTORS

Illinois Accelerator Research Center

Burn up Analysis for Fuel Assembly Unit in a Pressurized Heavy Water CANDU Reactor

Isotope Production at LERF

Incentivizing Domestic Production of Molybdenum-99 for Diagnostic Medicine

Thorium an alternative nuclear fuel cycle

LEU Conversion of the University of Wisconsin Nuclear Reactor

The Critical Need for Nuclear Medicine Radioisotopes and Research

UTILIZATION OF ETRR-2 AND COLLABORATION 1. INTRODUCTION

AREVA Back-End Possibilities for the Used Fuel of Research Test Reactors

Status of the FRM-II Project at Garching. Hans-Jürgen Didier, Gunter Wierheim Siemens AG, Power Generation (KWU), D Erlangen

DECOMMISSIONING OF THE IFIN-HH VVR-S NUCLEAR RESEARCH REACTOR Dr. Mitica Dragusin, IFIN-HH, Romania

Nuclear Energy Revision Sheet

PALLAS A nuclear reactor

Jamison Reifsteck and Even Lydon. Sustainable and Renewable Energy. Dr. Beck Thorium

The Nuclear Fuel Cycle Lecture 5

WM2012 Conference, February 26 March 1, 2012, Phoenix, Arizona, USA. Opportunities for the Multi Recycling of Used MOX Fuel in the US

A Clean, Secure Nuclear Energy Solution for the 21 st Century Advanced Reactor Concepts, LLC (ARC) June 2010

DEVELOPMENT OF EDUCATION AND TRAINING PROGRAMS USING ISIS RESEARCH REACTOR

IAEA Technical Meeting on Products and Services of Research Reactors 28 June 2 July 2010 IAEA, Vienna, Austria

KIPT ADS Facility. Yousry Gohar 1, Igor Bolshinsky 2, Ivan Karnaukhov 3. Argonne National Laboratory, USA 2. Idaho National Laboratory, USA 3

MCNP5 CALCULATIONS COMPARED TO EXPERIMENTAL MEASUREMENTS IN CEA-MINERVE REACTOR

Temperature Rise in LCLS-II Cavity Bellows

The new material irradiation infrastructure at the BR2 reactor. Copyright 2017 SCK CEN

THE ROLE OF REGULATORY AUTHORITY IN SAFE OPERATION OF RESEARCH REACTOR

Experimental Potentialities of the MBIR Reactor

Cyclotron & Medical Isotopes Best Theratronics announces plans to address the medical isotope shortage by manufacturing a range of cyclotrons

Medical isotope production in Australia:

NOVEL UTILIZATION OF TRIGA REACTORS

Neutronics Simulations of 237 Np Targets to Support Safety-Basis and 238 Pu Production Assessment Efforts at the High Flux Isotope Reactor

Transcription:

Medical Isotope Production by Electron Accelerators R.S. Orr University of Toronto

Power Reactor Uranium Fission Chain reaction neutrons

ANSTO's Open Pool Australian Lightwater (OPAL) Reactor is a state-of-the-art 20 Megawatt reactor that uses low enriched uranium fuel and is cooled by water.

First Fuel Rod View into Reactor Pool

Cherenkov Radiation from reactor under power

NU Reactor at Chalk River

Resonant Accelerator Concept Ising - 1924, Wideroe - 1928 Alternating (radio frequency) fields allow higher voltages The acceleration occurs in the electric field between cylindrical drift tubes. The RF power must be synchronised with the motion of the electrons, so that acceleration occurs in every gap. Linear Accelerator = LINAC

elinac 1.3 GHz ILC Technology Cornell/Orsay (DC) Coupler TESLA/ILC 9-Cell Cavity ILC Main LINAC Cryomodule

Current Issues in Isotope Production used in 80% of all nuclear medicine procedures. is supplied via generator. is produced by fission of Two major producers AECL NRU reactor (Canada) Covidien HFR reactor (Netherlands)

Current Demand In North America US - ~70,000 procedures daily using Canada about 7% of this Half life of is 66 hours, 20% decays each day 6-day curie is unit of measurement Amount available for use after 6 days North America uses ~7,000 6-day-Ci per week World demand is ~ 12,000 6-day-Ci

Current Production Process Reactor used to irradiate Highly Enriched Uranium (HEU) target with neutrons Reactor downside HEU weapons proliferation issue Target waste stream Reactor safety issues Reactor licensing Reactor decommissioning

Overview of Production Chain

Time Critical Process

Major Producers and Suppliers MDS Nordion (AECL, Canada) 40% (60%) Covidien (Netherlands) 25% (40%) Institut National des Radioélements (Belgium) 20% (0%) Nuclear Technology Products (South Africa) 10% (0%) Australian Nuclear Science & Technology Organization 0 (0)

Reactors NRU (Canada) 135 MW, started 1957 HFR (Netherlands) 45 MW, started in 1961 BR2 (Belgium) 100 MW, started 1961 SAFARI (South Afrika) 20MW, started in 1965 Osiris (France) 70 MW, started in 1966 OPAL (Australia) 20 MW, started in 2007

Some Facts Most reactors mentioned use Highly Enriched Uranium OPAL uses 25% North American Production need 6000 6-day curies/ week 50% of global demand Most reactors are aging OPAL cannot supply North American needs

Reactor In-service date Target uranium enrichment type NRU (Canada) BR2 (Belgium) HFR (Netherlands) SAFARI (South Africa) 1957 HEU 1961 HEU 1963 HEU 1965 HEU

Critical Mass of vs Enrichment Level

Reactor Reliability Issues NRU shutdown for 3 weeks late 2007. May 2008 Heavy water leak return to service 1 st quarter 2010 Canadian government get out of isotope business HFR technical problems in 2008 back in 2009. Replacement due 2015++ BR2 shut down in Fall 20008 due to release. OPAL startup delayed to 2008 on power. Osiris replaced by Jules Horowitz 2014 at most 25% of world supply Near term solution is supplying local needs from cyclotrons

Canadian Solution MDS-Nordion contracted AECL to construct two reactors. 10 MW HEU principally MAPLE 1 2000 MAPLE 2 2003 Simulations showed power coefficient reactivity 0.12mk/MW Measurement +0.28mk/MW Not understood problem for license Cancelled May 2008 $Millions down the drain..

Present Process -Reactor Non HEU Alternatives Reactor Electron Accelerator Electron Accelerator

Neutron Capture For a reactor flux of Secular equilibrium after 14 days 2.6 six-day-ci per gm. Low activity cf. 150 6-day-Ci for HEU reactor process Advantage No target waste stream. Disadvantages Major change in technology of separation of two Mo isotopes for generator + low activity High Flux reactor based technique

Photo-neutron 50 MeV, 500 kw electron accelerator Bremsstrahlung irradiator Electron beam High Z converter e.g. liquid Hg target

Photo-neutron 500 kw accelerator After 14 days 21 six-day-ci per gm. High activity

Photo-neutron Advantages No target waste stream. Ease of licensing. Cost and scheduling more predictable for accelerator. Disadvantages Major change in generator technology because of different target. Clinical testing/approval for new product. Cost of target 10% isotope.

Giant Dipole Resonance & Photo-fission W.T. Diamond / Nuclear Instruments and Methods in Physics Research A 432 (1999) 471}482

Giant Dipole Resonance (GDR) Bremstrahlung and Photofission

Yield Comparison Neutron induced Flux of gives fission in reactor: 15kW/gm Aluminum matrix to absorb power. At 6% yield 150 6-day-Ci per gram. Photo-fission of in an electron accelerator: Assume 50% of energy of 50 MeV machine into photons 0-50MeV. 45% overlap with GDR (10 20 MeV ) concentrated at 15 MeV. 11.25kW of photons at 15MeV per ma of beam current. γ fission rate/gm of in 50 kw beam is At 6% yield 0.86 6-day-Ci per gram. Need about 200 times target material - is cheap.

Can We Really Get 6% Yield?

Advantages of Accelerator over Reactor Can be quickly turned on and off no consequences. Does not produce radioactive waste from operation. Target waste is similar to reactor solution. Yield is not sensitive to use of LEU or HEU. Proliferation issue. Scalable technology. Additional accelerators can be turned on/off to meet demand. Licensing & decommissioning straightforward.

Caveats on Accelerator New technology intrinsically unproven. Substantial R&D e.g. high power target. Irradiated material may not be compatible with existing HEU recover and refinement facilities. Remains to be seen if it is economically competitive.

Accelerator Requirements Progress in technology has made high power electron accelerators an economic proposition. Notably super conducting radio frequency cavities. Power efficiency. Compactness. High accelerating gradient. Need several MegaWatts at 100% duty factor. 50 MeV at 100 ma 5 MWatt machine Two frequencies have commercial klystrons etc. 704 MHz 1.3 GHz

704MHz Option Based on Brookhaven Energy Recovery LINAC. 100 ma, 704MHz, 140 pc per bunch. Single cryomodule housing 5x5-cell superconducting RF cavities. 10 MeV per cavity 100 ma => 1MW per cavity 2x500kW klystrons. Wall-plug efficiency 40% (klystrons 60%) => 12MW for 2K cavities. 704MHz allows 4K operation of cavities several advantages Reduced complexity, lower operating and capiotal costs. C$60 Million.

1.3 GHz Option Scaled version of Cornell 0.5 MW 1.3GHz LINAC. 50x 2-cell cavities driven by 50 klystrons 5 MW 5 cells per cryostat C$125 Million

704MHz 704MHz versus 1.3GHz Frequency is in TV broadcast range. Klystrons less specialized than 1.3G Hz. RF structures have large apertures. Reduces wake-field problems. RF input couplers can operate at higher power levels than 1.3 GHz. Fewer components- lower cost + reliability. 4 K operation. 1.3 GHz Synergy with other projects in many Labs. International Linear Collider. Free electron lasers. 3 rd generation light sources.

Plans Target E-linac using SRF New 50 MeV electron LINAC funded By Canada Foundation for Innovation Isotope Production Isotopes for Medicine Isotopes for Physics Develop, deploy, & transfer SRF technology to Canadian industry Produce novel isotope beams for nuclear physics and materials science Demonstrate a transformative approach for producing medical isotopes Fission Yield (%) 99 Mo 132 Sn 70 80 90 100 110 120 130 140 150 160 Mass Number

elinac

elinac Time Evolution

Proof of Principle (2010-2012)

Proof of Principle (2010-2012) Assemble test accelerator system. Based on elinac injection cryomodule (ICM) Fabricate and commission targets with MDS Nordion. Transfer hot target to extraction system. Purify Mo-99 Quality control ICM fabrication in Collaboration with Variable Energy Cyclotron Centre (VECC) in Kolkata

Yield of 6-day-Ci vs Energy and Power

Target System Target system a challenge Production system 750 kw of γ and fission - 5 converters each followed by 10 targets - 15 kw per target Liquid Hg or water cooled W Proof of Principle (50kW) Power in converter 25kW Power in target 15 kw

Conclusion High Power elinacs can be a viable alternative to reactors for the production of